Nanogen To Host Conference Call on 2003 Third Quarter Financial Results.Business Editors SAN DIEGO, Calif.--(BUSINESS WIRE)--Oct. 24, 2003 Nanogen, Inc. (Nasdaq:NGEN NGEN Next Generation NGEN Next Generation Enterprise Network (US Navy Intranet Development Program) ) will host a conference call on Wednesday, October 29, 2003 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 third quarter financial results. The earnings release will be issued at close of market on October 29. Nanogen management will host the conference call. Audio of the management's presentation will be available via live webcast on the investor relations Investor relations The process by which the corporation communicates with its investors. section of Nanogen's corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available two hours after the completion of the conference call on October 29 until midnight on October 31, which may be accessed via telephone at (800) 642- 1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 3610320, will be required to listen to the playback. About Nanogen Inc. Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , hereditary hemochromatosis Hemochromatosis Definition Hemochromatosis is an inherited blood disorder that causes the body to retain excessive amounts of iron. This iron overload can lead to serious health consequences, most notably cirrhosis of the liver. , cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , beta thalassemia Thalassemia Definition Thalassemia describes a group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygen-carrying protein inside the red blood cells. and Canavan disease Canavan disease Spongy degeneration of CNS An early onset AR condition caused by a defect or deficiency of aspartoacylase resulting in accumulation of N-acetylaspartic acid in brain, primarily in Jews Clinical Atonia of neck muscles, hyperextension of legs, flexion . The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen's website at www.nanogen.com Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company's NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company's Form 10- K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion